<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530581</url>
  </required_header>
  <id_info>
    <org_study_id>2081-076</org_study_id>
    <nct_id>NCT01530581</nct_id>
  </id_info>
  <brief_title>Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation</brief_title>
  <official_title>A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <brief_summary>
    <textblock>
      This is a Randomized Multicentre study Comparing GCSF Mobilized Peripheral Blood and GCSF&#xD;
      stimulated Bone Marrow in Patients undergoing matched sibling Transplantation for&#xD;
      Haematologic Malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>2 years</time_frame>
    <description>The use of G-BM is associated with a longer time to treatment failure (extensive chronic GVHD, relapse, death) than is the use of G-PB for adult myeloablative allogeneic transplantation for hematologic malignancies.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Transplantation for Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>G-BM Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>G-PB Transplant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>G-PB Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>G-PB Transplant</intervention_name>
    <description>G-PB Transplant</description>
    <arm_group_label>G-PB Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>G-BM Transplant</intervention_name>
    <description>G-BM Transplant</description>
    <arm_group_label>G-BM Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient must&#xD;
&#xD;
               1. Be between the ages of 16 and 65 years old&#xD;
&#xD;
               2. Have one of the following hematologic malignancies:&#xD;
&#xD;
                    -  Acute myeloid leukemia (de novo, secondary or therapy related) in untreated&#xD;
                       1st relapse or in remission or with evidence of molecular relapse but blasts&#xD;
                       less than 5%&#xD;
&#xD;
                    -  Chronic myeloid leukemia in chronic or accelerated phase (de novo or therapy&#xD;
                       related)&#xD;
&#xD;
                    -  Myelodysplasia (de novo or therapy related)&#xD;
&#xD;
                    -  Other hematologic malignancy (de novo or therapy related) including but not&#xD;
                       limited to: ALL (CR 1, CR2 or CR3), CLL, non-Hodgkin's lymphoma, Hodgkin's&#xD;
                       lymphoma&#xD;
&#xD;
               3. Must be receiving a myeloablative conditioning regimen of busulfan and&#xD;
                  cyclophosphamide or TBI and cyclophosphamide or other myeloablative regimen&#xD;
                  approved by the Clinical Study Chair. (Regimens containing ATG are not allowed.)&#xD;
&#xD;
               4. Have an HLA-identical sibling donor&#xD;
&#xD;
               5. Meet the transplant centre's criteria for myeloablative allogeneic&#xD;
                  transplantation*&#xD;
&#xD;
               6. Have an ECOG performance status of 0, 1 or 2&#xD;
&#xD;
               7. Have given signed informed consent&#xD;
&#xD;
        Donor must&#xD;
&#xD;
          1. Be 18 years of age or older. (Upper age limit is at the discretion of the transplant&#xD;
             physician at the collection centre.)&#xD;
&#xD;
          2. Be able to undergo general anesthesia and BM harvest or peripheral blood collection as&#xD;
             per assessment by a transplant physician. (If an anesthetist assesses a donor after&#xD;
             randomization and determines the donor should not undergo general anesthesia, then the&#xD;
             donor and recipient will be withdrawn from the study.)&#xD;
&#xD;
          3. Be a sibling of the recipient&#xD;
&#xD;
          4. Be a 6/6 HLA match of the recipient. HLA typing is by serologic or DNA methodology for&#xD;
             A and B and by DNA methodology for A and B and by DNA methodology for DRB1&#xD;
             (intermediate resolution)&#xD;
&#xD;
          5. Have given signed informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Recipient&#xD;
&#xD;
        1. The recipient is HIV antibody positive&#xD;
&#xD;
        Donor&#xD;
&#xD;
          1. The donor is unable to undergo general anesthesia, bone marrow harvest or peripheral&#xD;
             blood collection&#xD;
&#xD;
          2. The donor is pregnant or breastfeeding at the time of progenitor cell collection&#xD;
&#xD;
          3. The donor has a history of malignant disease within the last 5 years or current&#xD;
             malignancy other than non-melanomatous in situ skin carcinoma or cervical carcinoma in&#xD;
             situ&#xD;
&#xD;
          4. The donor is HIV antibody positive&#xD;
&#xD;
          5. The donor has a known sensitivity to E. coli-derived products&#xD;
&#xD;
          6. The donor and recipient are identical twins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Al Jurf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital &amp; Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

